Bristol Myers Squibb

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Bristol Myers Squibb Expands AI Infrastructure With Nvidia DGX Vera Rubin - $Bristol Myers Squibb(BMY.US) $NVIDIA(NVDA.US)

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ 𝐁𝐫𝐢𝐬𝐭𝐨𝐥 𝐌𝐲𝐞𝐫𝐬 𝐒𝐪𝐮𝐢𝐛𝐛 will deploy an 𝐍𝐯𝐢𝐝𝐢𝐚 𝐃𝐆𝐗 𝐒𝐮𝐩𝐞𝐫𝐏𝐎𝐃.

➤ Infrastructure includes 𝐃𝐆𝐗 𝐕𝐞𝐫𝐚 𝐑𝐮𝐛𝐢𝐧 𝐍𝐕𝐋𝟕𝟐 systems.

➤ Vera Rubin delivers up to 𝐈𝟎𝐱 greater performance per megawatt.

➤ AI infrastructure will support research across 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲, 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲, and neuroscience.

➤ BMS will develop 𝐀𝐈 𝐟𝐨𝐮𝐧𝐝𝐚𝐭𝐢𝐨𝐧 𝐦𝐨𝐝𝐞𝐥𝐬 using proprietary data.

➤ Platform will power 𝐚𝐠𝐞𝐧𝐭𝐢𝐜 𝐀𝐈 workflows for drug discovery.

➤ BMS will use its 𝐏𝐫𝐞𝐝𝐢𝐜𝐭 𝐅𝐢𝐫𝐬𝐭 approach to guide experiments.

➤ Agreement includes access to 𝐍𝐯𝐢𝐝𝐢𝐚 𝐁𝐢𝐨𝐍𝐞𝐌𝐨 and Agent Toolkit.

➤ Financial terms of the collaboration were 𝐧𝐨𝐭 𝐝𝐢𝐬𝐜𝐥𝐨𝐬𝐞𝐝.

👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭𝐬:

𝐆𝐫𝐞𝐠 𝐌𝐞𝐲𝐞𝐫𝐬, Chief Digital and Technology Officer at Bristol Myers Squibb:

"BMS has made a deliberate bet on AI, and we are beginning to see it pay off in our pipeline and operations. Expanding our compute capabilities with Nvidia gives our researchers and teams across the business the scale they need to keep BMS at the leading edge of what AI can do for drug discovery and development."

𝐑𝐨𝐛𝐞𝐫𝐭 𝐏𝐥𝐞𝐧𝐠𝐞, Executive Vice President and Chief Research Officer at Bristol Myers Squibb:

"The goal isn't speed for its own sake; it's raising the probability that each program we advance is the right one."

𝐑𝐨𝐫𝐲 𝐊𝐞𝐥𝐥𝐞𝐡𝐞𝐫, Senior Director of Business Development, Healthcare and Life Sciences at Nvidia:

"The tools will allow BMS to convert its scientific data into proprietary intelligence to support molecule design and hypothesis evaluation."

Something to keep an eye on

Rep. Mike Kelly (R) just filed a sale of up to $50,000 of $Bristol Myers Squibb(BMY.US)

Kelly sits on the House Ways & Means Subcommittee on Health

That subcommittee makes the Medicare laws that control how much the government pays for prescription drugs

Including Bristol-Myers' biggest drug, Eliquis, is one where the government now sets the price